Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation

NCT03192397 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT03192397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03192397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 9, 2017
Completion date
May 21, 2027
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia in remission, adult acute lymphoblastic leukemia in complete remission, chronic myelogenous leukemia, bcr-abl1 positive in remission, chronic myelomonocytic leukemia in remission, graft versus host disease, hodgkin lymphoma, minimal residual disease, myelodysplastic syndrome, myeloproliferative neoplasm, non-hodgkin lymphoma, plasma cell myeloma, severe aplastic anemia, waldenstrom macroglobulinemia